Comment by Todd E. Morgan and Caleb E. Finch—Posted 31 March 2005
The benefits of caloric restriction (CR) to normal brain aging have been a long-standing interest in our lab. In a rat model we showed that CR attenuates age-associated activation of astrocytes and microglia, which have implications on oxidative stress (Morgan et al., 1997; 1999). More recently, in collaboration with David Morgan (no relation to T.E. Morgan), we showed that CR attenuates amyloid deposition and glial activation in two unique transgenic mouse models of AD-related amyloidosis (Patel et al., 2005; NOTE: This paper was accepted on September 20, 2004 and initially scheduled for publication in 2004 by Neurobiology of Aging, as shown on the proofs). We examined the brains from mice possessing either mutated amyloid β precursor protein (APPswe/ind) alone (Mucke et al., 2000) or mutated APPswe and presenilin 1M146L (APP+PS1)(Holcomb et al., 1998). Both transgenics develop senile plaques by six months of age. As little as six weeks of CR substantially decreased the accumulation of Aß deposits. However, CR did not decrease APP levels. Of course, turnover of APP, Aβ, and other products must be determined before excluding effects of CR on processing, deposition and/or degradation. The likely involvement of astrocytes is predicted since CR attenuated astrocytic activation in this model. In particular, CR regulates astrocyte-derived apolipoproteins E & J (Morgan et al., 1999); both apoE and apoJ have a profound effect on Aβ deposition (DeMattos et al., 2004). Evidence for additional pathways was reported in Wang et al. (2005) which showed that a reduction in carbohydrate intake in Tg2576 mice influenced both Aβ processing (increase in α-secretase) and degradation (increase in insulin-degrading enzyme).
Our CR regime consists of the reduction in total calories (40%) from all energy sources (carbohydrates, proteins and fats) while maintaining micronutrients. Therefore, the effects of CR do not depend on restriction of a particular energy source. Thus, the benefit of reducing only carbohydrates (as in the Wang study) is mainly attributable to the general reduction in total calorie intake.
A key question is raised by these studies: will CR slow the progression of Aβ deposition once deposits are already present? We have unpublished data suggesting that it will. At the 9th International Conference on Alzheimer's Disease and Related Disorders meeting in Philadelphia (July 2004), we showed data that Aβ deposition is reduced even if CR is initiated after Aβ deposits are already present. For this study we varied the age at CR initiation and found that the CR mice always had fewer plaques. However, we do not know whether CR affects established plaques. In this study we also determined that a 20% reduction in calories was sufficient (not published).
Since CR affects a myriad of physiological pathways (e.g., lowers glucose, lowers insulin, increases glucocorticoids) (Patel et al., 2002), it will be critical to determine if the beneficial affects we see in our transgenic models require more than one of these pathways. On-going experiments to manipulate single pathways should answer this question. Regardless of the mechanism the penultimate question remains: What is the ideal body mass index required to minimize age- and disease-related neurodegenerative events?
References:
DeMattos R. B., Cirrito J. R., Parsadanian M., May P. C., O'Dell M. A., Taylor J. W., Harmony J. A., Aronow B. J., Bales K. R., Paul S. M. and Holtzman D. M. (2004) ApoE and Clusterin Cooperatively Suppress Abeta Levels and Deposition. Evidence that ApoE Regulates Extracellular Abeta Metabolism In Vivo. Neuron 41: 193-202. Abstract
Holcomb, L., Gordon, M.N., McGowan, E., Yu, X., Benkovic, S., Jantzen, P., Wright, K., Saad, I., Mueller, R., Morgan, D., Sanders, S., Zehr, C., O'Campo, K., Hardy, J., Prada, C.M., Eckman, C., Younkin, S., Hsiao, K. and Duff, K., (1998) Accelerated Alzheimer-type phenotype in transgenic mice carrying both mutant amyloid precursor protein and presenilin 1 transgenes, Nat Med, 4: 97-100. Abstract
Patel, N.V. and Finch, C.E. (2002) The glucocorticoid paradox of caloric restriction in slowing brain aging, Neurobiol Aging, 23: 707-17. Abstract
Patel, N.V., M. N. Gordon, K. E. Connor, R. A. Good, R. W. Engelman, J. Mason, D. G. Morgan, T. E. Morgan, C. E. Finch (2005) "Caloric Restriction Attenuates Aß-deposition in Alzheimer Transgenic Models." Neurobiol Aging 26/7: 995-1000. Abstract
Morgan, T. E., I. Rozovsky, S. K. Goldsmith, D. J. Stone, T. Yoshida and C. E. Finch (1997) Increased transcription of the astrocyte gene GFAP during middle-age is attenuated by food restriction: implications for the role of oxidative stress. Free Radic Biol Med 23: 524-8. Abstract
Morgan, T. E., Z. Xie, S. Goldsmith, T. Yoshida, A. S. Lanzrein, D. Stone, I. Rozovsky, G. Perry, M. A. Smith and C. E. Finch (1999) The mosaic of brain glial hyperactivity during normal ageing and its attenuation by food restriction. Neuroscience 89: 687-99. Abstract
Mucke, L., Masliah, E., Yu, G.Q., Mallory, M., Rockenstein, E.M., Tatsuno, G., Hu, K., Kholodenko, D., Johnson-Wood, K. and McConlogue, L. (2000) High-level neuronal expression of abeta 1-42 in wild-type human amyloid protein precursor transgenic mice: synaptotoxicity without plaque formation, J Neurosci, 20: 4050-8. Abstract
Wang J, Ho L, Qin W, Rocher AB, Seror I, Humala N, Maniar K, Dolios G, Wang R, Hof PR, Pasinetti GM. Caloric restriction attenuates beta-amyloid neuropathology in a mouse model of Alzheimer's disease." FASEB J. 2005. Abstract